Log in

NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Forecast & News

$9.02
+0.31 (+3.56 %)
(As of 01/21/2020 03:07 AM ET)
Today's Range
$8.74
Now: $9.02
$9.14
50-Day Range
$7.03
MA: $8.60
$9.22
52-Week Range
$4.52
Now: $9.02
$11.11
Volume186,276 shs
Average Volume102,269 shs
Market Capitalization$244.80 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Book Value$2.14 per share

Profitability

Net Income$-73,960,000.00
Net Margins-4,013.45%

Miscellaneous

Employees38
Market Cap$244.80 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.


Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its earnings results on Thursday, November, 7th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.07. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.45% and a negative return on equity of 110.20%. View Syndax Pharmaceuticals' Earnings History.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syndax Pharmaceuticals.

What price target have analysts set for SNDX?

6 brokers have issued 12 month price targets for Syndax Pharmaceuticals' stock. Their forecasts range from $5.00 to $19.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $14.20 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

What is the consensus analysts' recommendation for Syndax Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

Has Syndax Pharmaceuticals been receiving favorable news coverage?

News headlines about SNDX stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Syndax Pharmaceuticals.

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 594,700 shares, an increase of 12.5% from the November 28th total of 528,700 shares. Based on an average daily trading volume, of 147,900 shares, the short-interest ratio is presently 4.0 days. Currently, 2.9% of the shares of the stock are short sold. View Syndax Pharmaceuticals' Current Options Chain.

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Verastem (VSTM), Clearside Biomedical (CLSD), Progenics Pharmaceuticals (PGNX) and TG Therapeutics (TGTX).

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)
  • Mr. Michael A. Metzger, Pres & COO (Age 48)
  • Mr. Richard P. Shea, CFO & Treasurer (Age 67)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $9.02.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $244.80 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Treasury Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel